Asia Quadruples the MRNA Tech Transfer Consortia to Accelerate Vaccine Development

mRNA continues to be white hot technology, despite studies demonstrating some challenges still to overcome. Positioned as a decisive move to propel the mRNA Technology Transfer Programme, four South-East Asia research consortia will be formalized at the culmination of Day 1 of the World Health Organization (WHO) and Medicines Patent Pool (MPP) mRNA Technology Transfer Program’s regional meeting in Singapore.

The research institutions signing this commitment represent diverse fields, including health, product research, and development, and acknowledge the transformative potential of the mRNA Technology Transfer Programme in low- and middle-income countries (LMICs). Their collective commitment extends to collaborative research consortia focused on developing mRNA vaccines targeting dengue, enterovirus-A71/Coxsackie, human papillomavirus, and Plasmodium vivax – diseases severely affecting the region. The consortia pledge to share material, data, and intellectual property equitably and non-exclusively with the Programme Partners.